RVTY

+ Watchlist + Portfolio

Revvity, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $119.45
52-Week Range: $81.22 – $124.42
Market Cap: $13.85B
P/E (TTM): 59.68
EPS (TTM): 2.08
Dividend Yield: 0.23%

Advanced Metrics

Price/Book: 1.92
PEG Ratio: 0.74
Return on Equity: 3.21%
Return on Assets: 2.37%
Gross Margin: 54.98%
Operating Margin: 17.05%
Profit Margin: 8.16%
Current Ratio: 1.80
Debt/Equity: 0.46
Total Debt: $3.34B
Free Cash Flow: $604.99M
Revenue Growth: 1.30%
Earnings Growth: 1.20%
Enterprise Value: $15.65B

RVTY Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$3.31B	$2.75B	$2.76B	$2.86B
Cost of Revenue	$1.32B	$1.21B	$1.22B	$1.29B
Gross Profit	$1.99B	$1.54B	$1.54B	$1.56B
Research & Development	$221.62M	$216.58M	$196.84M	$215.84M
Selling, General & Admin	$1.03B	$1.02B	$994.07M	$991.89M
Operating Expenses	$1.25B	$1.24B	$1.19B	$1.21B
Operating Income	$742.70M	$300.56M	$346.74M	$356.63M
EBITDA	$1.18B	$713.56M	$840.25M	$765.80M
Pretax Income	$651.84M	$182.98M	$316.13M	$268.28M
Income Tax	$139.16M	$3.47M	$33.05M	$28.39M
Net Income	$569.18M	$693.09M	$270.38M	$241.20M
Diluted EPS	4.58	5.55	2.20	2.07
Diluted Shares	126.43M	124.81M	122.82M	116.59M

RVTY Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$454.36M	$913.16M	$1.16B	$919.86M
Receivables	$612.78M	$632.81M	$632.40M	$744.67M
Inventory	$405.46M	$428.06M	$367.59M	$379.50M
Current Assets	$3.29B	$3.00B	$2.35B	$2.24B
Total Assets	$14.13B	$13.56B	$12.39B	$12.17B
Current Liabilities	$1.54B	$1.45B	$653.10M	$1.33B
Long-Term Debt	$3.92B	$3.18B	$3.15B	$2.63B
Total Debt	$4.60B	$4.07B	$3.33B	$3.40B
Total Liabilities	$6.75B	$5.69B	$4.73B	$4.92B
Retained Earnings	$4.95B	$5.61B	$5.85B	$6.05B
Shareholders' Equity	$7.38B	$7.87B	$7.67B	$7.25B
Working Capital	$1.74B	$1.55B	$1.70B	$908.50M
Net Debt	$3.94B	$2.99B	$1.99B	$2.30B

RVTY Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$679.81M	$91.27M	$628.30M	$582.93M
Capital Expenditure	-$85.63M	-$81.37M	-$86.65M	-$73.52M
Free Cash Flow	$594.18M	$9.90M	$541.65M	$509.41M
Depreciation & Amortisation	$427.00M	$431.77M	$427.85M	$405.34M
Stock-Based Compensation	$51.52M	$41.41M	$37.81M	$22.85M
Investing Cash Flow	-$132.85M	$1.31B	$776.16M	-$17.35M
Financing Cash Flow	-$661.80M	-$947.12M	-$1.13B	-$857.52M
Dividends Paid	-$35.34M	-$34.97M	-$34.45M	-$32.80M
Share Repurchases	-$80.64M	-$388.88M	-$369.58M	-$820.82M
Net Change in Cash	-$114.84M	$457.68M	$276.23M	-$291.94M

RVTY Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$664.76M	$720.28M	$698.95M	$772.06M	$711.12M
Cost of Revenue	$289.22M	$327.73M	$324.35M	$350.40M	$323.46M
Gross Profit	$375.55M	$392.56M	$374.60M	$421.66M	$387.65M
Research & Development	$53.60M	$53.27M	$50.80M	$58.18M	$57.89M
Selling, General & Admin	$249.72M	$250.22M	$241.91M	$251.73M	$253.88M
Operating Expenses	$303.32M	$303.49M	$292.71M	$309.91M	$311.77M
Operating Income	$72.23M	$89.06M	$81.90M	$111.75M	$75.89M
EBITDA	$172.77M	$194.37M	$180.52M	$218.15M	$179.77M
Pretax Income	$52.38M	$68.65M	$55.69M	$91.56M	$49.99M
Income Tax	$10.71M	$13.43M	$8.46M	-$4.21M	$9.10M
Net Income	$42.24M	$53.95M	$46.65M	$98.36M	$40.72M
Diluted EPS	0.35	0.46	0.40	0.87	0.36
Diluted Shares	120.23M	117.54M	115.46M	113.21M	111.88M

RVTY Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$1.14B	$991.85M	$931.39M	$919.86M	$860.32M
Receivables	$617.42M	$661.14M	$680.26M	$744.67M	$691.38M
Inventory	$381.31M	$388.47M	$379.92M	$379.50M	$387.50M
Current Assets	$2.32B	$2.24B	$2.14B	$2.24B	$2.13B
Total Assets	$12.36B	$12.36B	$12.14B	$12.17B	$12.00B
Current Liabilities	$648.19M	$671.81M	$1.22B	$1.33B	$1.24B
Long-Term Debt	$3.17B	$3.21B	$2.63B	$2.63B	$2.63B
Total Debt	$3.33B	$3.37B	$3.37B	$3.40B	$3.35B
Total Liabilities	$4.72B	$4.81B	$4.76B	$4.92B	$4.81B
Retained Earnings	$5.88B	$5.93B	$5.96B	$6.05B	$6.09B
Shareholders' Equity	$7.64B	$7.56B	$7.38B	$7.25B	$7.18B
Working Capital	$1.67B	$1.56B	$921.04M	$908.50M	$889.67M
Net Debt	$2.03B	$2.22B	$2.28B	$2.30B	$2.35B

RVTY Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	$128.16M	$134.32M	$138.50M	$181.96M	$115.23M
Capital Expenditure	-$15.98M	-$18.87M	-$18.50M	-$20.17M	-$19.77M
Free Cash Flow	$112.17M	$115.45M	$120.00M	$161.79M	$95.45M
Depreciation & Amortisation	$97.42M	$102.78M	$102.06M	$103.08M	$105.06M
Stock-Based Compensation	$7.73M	$10.13M	$9.05M	-$4.07M	$8.71M
Investing Cash Flow	-$6.38M	-$9.49M	$18.97M	-$20.45M	-$78.27M
Financing Cash Flow	-$163.66M	-$302.48M	-$215.07M	-$176.31M	-$88.89M
Dividends Paid	-$8.43M	-$8.28M	-$8.13M	-$7.96M	-$7.84M
Share Repurchases	-$153.59M	-$293.91M	-$205.03M	-$168.28M	-$86.50M
Net Change in Cash	-$41.89M	-$177.65M	-$57.60M	-$14.80M	-$51.94M

Market Snapshot

About

Revvity, Inc., formerly PerkinElmer, is a global provider of health science solutions spanning diagnostics, life sciences, and applied markets. The company offers instruments, software, services, and consumables for drug discovery, clinical diagnostics, food safety, and environmental testing. Revvity serves pharmaceutical, biotech, diagnostic, academic, and government customers worldwide.